Antibe Therapeutics (ATBPF) 0.1330 $ATBPF Antib
Post# of 273322
Posted On: 07/26/2016 7:01:23 PM
Antibe Therapeutics (ATBPF) 0.1330 $ATBPF
Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
BusinessWire - Mon Jun 20, 4:45PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE) closed the second and final closing of its previously announced non-brokered private placement of units, raising gross proceeds of $486,500 (the "Offering" and total gross proceeds of $1,455,000 including the first closing on June 10, 2016. Under the terms of the Offering, 4,865,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until June 20, 2018.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
BusinessWire - Fri Jun 10, 3:45PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation" (TSXV:ATE, OTCQX:ATBPF) closed the first tranche of a non-brokered private placement of units, raising gross proceeds of $968,500 (the "Offering" . Under the terms of the Offering, 9,685,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until June 10, 2018.
ATE.VN: 0.170 (+0.010)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference
BusinessWire - Mon May 30, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3rd to 5th. The company's founder and Chief Scientific Officer, John Wallace, and Antibe Scientific Advisor and Nobel Prize winner Louis Ignarro, will be making podium presentations at the conference. A distinguished collaborator, University of Naples cancer researcher Professor Angela Ianaro, will present a lecture on the potential for treating and preventing melanoma with hydrogen sulfide, using drugs like ATB-346, Antibe's most advanced clinical candidate currently in a Phase 2 trial in osteoarthritis patients.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
BusinessWire - Mon May 02, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce that CEO Daniel Legault will be presenting at the fifth annual Bloom Burton & Co. Healthcare Investor Conference in Toronto to be held on May 2 - 3, 2016 at the Sheraton Centre Toronto Hotel. Bloom Burton & Co. will be hosting approximately 60 public and private Canadian healthcare companies and will attract Canadian, U.S. and international investors who will have the opportunity to obtain corporate updates from presenting companies.
Antibe Therapeutics Announces the Launch of PentOS OI(TM) Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery
BusinessWire - Mon Apr 18, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. ("Citagenix" has launched PentOS OI(TM) Putty, the first product of a new family of bone graft substitutes that have a proven ability to form bone. PentOS OI(TM) Putty will be available to oral and maxillofacial surgery customers and will be joined by three additional PentOS OI(TM) products that are expected to launch in the coming months: PentOS OI(TM) Flex, PentOS OI(TM) Sponge and PentOS OI(TM) Fill.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Appointment of the Giordano Group, Inc, a Division of Network 1 Financial Securities LLC, as US-BASED Investor Relations Consultant
BusinessWire - Thu Mar 31, 5:00PM CDT
Antibe Therapeutics Inc ("Antibe" or the "Company" (TSXV:ATE, OTCQX:ATBPF) has retained the Giordano Group, Inc ("Giordano Group" , a division of Network 1 Financial Securities LLC ("Network 1" , to provide investor relations consulting services for the United States.
ATE.VN: 0.170 (+0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Mar 10, 7:00PM CST
TSX VENTURE COMPANIES
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.03 (+0.13), ARQL: 1.61 (unch), AMGN: 167.67 (+1.11), ATNM: 1.73 (+0.01), AZN: 30.91 (-0.24), AVEO: 1.00 (+0.01), ABBV: 64.45 (+0.13), BXLT: 46.02 (-0.18), ARRY: 3.70 (+0.01)
Acquisition of Securities of Antibe Therapeutics Inc.
Marketwired - Wed Feb 03, 4:10PM CST
URIST Regenerative Med Inc. (previously OCFS Oral Cranial Facial Systems Inc.) ("URM" , 66 Avenue Road, #3, Toronto, Ontario M5R 3N8, announces that it has acquired 2,857,500 common shares (each, a "Common Share" of Antibe Therapeutics Inc. ("Antibe" in a share exchange transaction pursuant to which it sold its 90 common shares in Citagenix Inc. to Antibe (the "Acquisition" .
Antibe Therapeutics Closes Acquisition of Minority Interest in Citagenix Inc.
BusinessWire - Tue Feb 02, 5:10PM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc. ("Citagenix" , a Montreal-based sales and distribution company with a focus on regenerative medicine. The Citagenix acquisition was previously announced in Antibe's news releases of October 6, 2015 and October 16, 2015.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Payment in Kind Election
BusinessWire - Wed Jan 27, 7:48PM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV:ATE, OTCQX:ATBPF) announces it has elected to pay in kind all interest due January 15, 2016 under the Company's 10% senior secured convertible debentures due October 15, 2018 (the "Debentures" . The Debentures provide that Antibe may, at its sole option, elect to pay in kind certain interest payments.
ATE.VN: 0.170 (+0.010)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 25.15 (+0.41), ARWR: 5.75 (+0.10), PFE: 36.83 (+0.05), GLYC: 8.56 (-0.04), BMY: 75.06 (-0.50), DYAX: 38.04 (-0.37), CBPO: 119.74 (+6.60), JNJ: 125.15 (+0.26), AZN: 30.91 (-0.24), PLXP: (), ARNA: 1.67 (+0.01)
Antibe Therapeutics Signs Exclusive License & Distribution Agreement for Novel Bone Regenerating Biological Product
BusinessWire - Tue Jan 12, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. ("Induce" for the Canadian rights for Induce's URIST(TM) biological product for dental and craniofacial applications. URIST(TM) is a novel bone graft substitute that contains bone morphogenetic protein-2 (BMP), and is being developed as a means of promoting the regeneration of bone following dental and oral maxillofacial surgery. Animal studies have demonstrated the ability of URIST(TM) to potently stimulate bone re-growth. Orthobiologics (the use of biological approaches to regenerate and repair bone) is estimated to be a US$4.4 billion market. BMP-based products are among the largest segments of this market.
ATE.VN: 0.170 (+0.010)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 3.00 (+0.01), KMPH: 3.79 (-0.45), NKTR: 15.15 (-0.16), INSY: 15.51 (-0.28), AVXL: 7.49 (+0.03), PCRX: 36.69 (-0.97), REPH: 7.68 (-0.08), PTIE: 2.68 (-0.02)
Antibe Therapeutics Announces Brokered Private Placement
BusinessWire - Thu Dec 24, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company" (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the completion of a first closing of a brokered private placement (the "Private Placement" on the same financial terms as the previously disclosed non-brokered private placement completed in connection with the acquisition of Citagenix Inc. The Private Placement of 45 units (each, a "Unit" yielded gross proceeds of $450,000. Each Unit was priced at $10,000 and consists of a senior secured convertible debenture in the principal amount of $10,000.00 (each, a "Debenture" and 20,000 warrants (each, a "Warrant" . Bloom Burton & Co. Limited acted as agent in connection with the Private Placement.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Completion of Validation Studies of ATB-346, Progression to Phase 2 Clinical Trials
BusinessWire - Mon Dec 21, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" (TSXV: ATE, OTCQX: ATBPF) announced today the completion of the previously announced validation studies being performed on the Company's lead drug, ATB-346. These studies were initiated as a consequence of ATB-346 inducing an elevation of liver enzymes in some subjects taking the higher doses of the drug (750 and 1500 mg/day), and were aimed at gaining a better understanding of the drug's potency, absorption, metabolism and excretion characteristics. The results of these studies support progression to Phase 2 of development of this drug in patients with osteoarthritis.
ATE.VN: 0.170 (+0.010)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 16.57 (-0.04), PFE: 36.83 (+0.05), AMGN: 167.67 (+1.11), AMPE: 0.95 (unch), LLY: 82.09 (+0.11), NKTR: 15.15 (-0.16), AGN: 248.95 (+1.10), AZN: 30.91 (-0.24), ABBV: 64.45 (+0.13), POZN: 5.94 (-0.43), REGN: 398.27 (+3.37), PTIE: 2.68 (-0.02)
Antibe Therapeutics Reports Q2 2016 Interim Financial and Operating Results and Appoints New CFO
BusinessWire - Tue Dec 01, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015. The Corporation's unaudited Q2 2016 financial statements and MD&A are available on SEDAR.
ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
BusinessWire - Mon Jun 20, 4:45PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV: ATE) closed the second and final closing of its previously announced non-brokered private placement of units, raising gross proceeds of $486,500 (the "Offering" and total gross proceeds of $1,455,000 including the first closing on June 10, 2016. Under the terms of the Offering, 4,865,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until June 20, 2018. ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
BusinessWire - Fri Jun 10, 3:45PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
(TSXV:ATE, OTCQX:ATBPF) closed the first tranche of a non-brokered private placement of units, raising gross proceeds of $968,500 (the "Offering" . Under the terms of the Offering, 9,685,000 units (the "Units" were sold at a price of $0.10 per Unit, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant" with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share" at a price of $0.15 per Warrant Share until June 10, 2018. ATE.VN: 0.170 (+0.010)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference
BusinessWire - Mon May 30, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe"
(TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3rd to 5th. The company's founder and Chief Scientific Officer, John Wallace, and Antibe Scientific Advisor and Nobel Prize winner Louis Ignarro, will be making podium presentations at the conference. A distinguished collaborator, University of Naples cancer researcher Professor Angela Ianaro, will present a lecture on the potential for treating and preventing melanoma with hydrogen sulfide, using drugs like ATB-346, Antibe's most advanced clinical candidate currently in a Phase 2 trial in osteoarthritis patients. ATE.VN: 0.170 (+0.010)
Antibe Therapeutics to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
BusinessWire - Mon May 02, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe"
(TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce that CEO Daniel Legault will be presenting at the fifth annual Bloom Burton & Co. Healthcare Investor Conference in Toronto to be held on May 2 - 3, 2016 at the Sheraton Centre Toronto Hotel. Bloom Burton & Co. will be hosting approximately 60 public and private Canadian healthcare companies and will attract Canadian, U.S. and international investors who will have the opportunity to obtain corporate updates from presenting companies. Antibe Therapeutics Announces the Launch of PentOS OI(TM) Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery
BusinessWire - Mon Apr 18, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe"
(TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. ("Citagenix" has launched PentOS OI(TM) Putty, the first product of a new family of bone graft substitutes that have a proven ability to form bone. PentOS OI(TM) Putty will be available to oral and maxillofacial surgery customers and will be joined by three additional PentOS OI(TM) products that are expected to launch in the coming months: PentOS OI(TM) Flex, PentOS OI(TM) Sponge and PentOS OI(TM) Fill. ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Appointment of the Giordano Group, Inc, a Division of Network 1 Financial Securities LLC, as US-BASED Investor Relations Consultant
BusinessWire - Thu Mar 31, 5:00PM CDT
Antibe Therapeutics Inc ("Antibe" or the "Company"
(TSXV:ATE, OTCQX:ATBPF) has retained the Giordano Group, Inc ("Giordano Group" , a division of Network 1 Financial Securities LLC ("Network 1" , to provide investor relations consulting services for the United States. ATE.VN: 0.170 (+0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Thu Mar 10, 7:00PM CST
TSX VENTURE COMPANIES
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.03 (+0.13), ARQL: 1.61 (unch), AMGN: 167.67 (+1.11), ATNM: 1.73 (+0.01), AZN: 30.91 (-0.24), AVEO: 1.00 (+0.01), ABBV: 64.45 (+0.13), BXLT: 46.02 (-0.18), ARRY: 3.70 (+0.01)
Acquisition of Securities of Antibe Therapeutics Inc.
Marketwired - Wed Feb 03, 4:10PM CST
URIST Regenerative Med Inc. (previously OCFS Oral Cranial Facial Systems Inc.) ("URM"
, 66 Avenue Road, #3, Toronto, Ontario M5R 3N8, announces that it has acquired 2,857,500 common shares (each, a "Common Share" of Antibe Therapeutics Inc. ("Antibe" in a share exchange transaction pursuant to which it sold its 90 common shares in Citagenix Inc. to Antibe (the "Acquisition" . Antibe Therapeutics Closes Acquisition of Minority Interest in Citagenix Inc.
BusinessWire - Tue Feb 02, 5:10PM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company"
(TSXV:ATE, OTCQX:ATBPF) announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc. ("Citagenix" , a Montreal-based sales and distribution company with a focus on regenerative medicine. The Citagenix acquisition was previously announced in Antibe's news releases of October 6, 2015 and October 16, 2015. ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Payment in Kind Election
BusinessWire - Wed Jan 27, 7:48PM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company"
(TSXV:ATE, OTCQX:ATBPF) announces it has elected to pay in kind all interest due January 15, 2016 under the Company's 10% senior secured convertible debentures due October 15, 2018 (the "Debentures" . The Debentures provide that Antibe may, at its sole option, elect to pay in kind certain interest payments. ATE.VN: 0.170 (+0.010)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 25.15 (+0.41), ARWR: 5.75 (+0.10), PFE: 36.83 (+0.05), GLYC: 8.56 (-0.04), BMY: 75.06 (-0.50), DYAX: 38.04 (-0.37), CBPO: 119.74 (+6.60), JNJ: 125.15 (+0.26), AZN: 30.91 (-0.24), PLXP: (), ARNA: 1.67 (+0.01)
Antibe Therapeutics Signs Exclusive License & Distribution Agreement for Novel Bone Regenerating Biological Product
BusinessWire - Tue Jan 12, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe"
(TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. ("Induce" for the Canadian rights for Induce's URIST(TM) biological product for dental and craniofacial applications. URIST(TM) is a novel bone graft substitute that contains bone morphogenetic protein-2 (BMP), and is being developed as a means of promoting the regeneration of bone following dental and oral maxillofacial surgery. Animal studies have demonstrated the ability of URIST(TM) to potently stimulate bone re-growth. Orthobiologics (the use of biological approaches to regenerate and repair bone) is estimated to be a US$4.4 billion market. BMP-based products are among the largest segments of this market. ATE.VN: 0.170 (+0.010)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 3.00 (+0.01), KMPH: 3.79 (-0.45), NKTR: 15.15 (-0.16), INSY: 15.51 (-0.28), AVXL: 7.49 (+0.03), PCRX: 36.69 (-0.97), REPH: 7.68 (-0.08), PTIE: 2.68 (-0.02)
Antibe Therapeutics Announces Brokered Private Placement
BusinessWire - Thu Dec 24, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Company"
(TSXV: ATE, OTCQX: ATBPF) is pleased to announce the completion of a first closing of a brokered private placement (the "Private Placement" on the same financial terms as the previously disclosed non-brokered private placement completed in connection with the acquisition of Citagenix Inc. The Private Placement of 45 units (each, a "Unit" yielded gross proceeds of $450,000. Each Unit was priced at $10,000 and consists of a senior secured convertible debenture in the principal amount of $10,000.00 (each, a "Debenture" and 20,000 warrants (each, a "Warrant" . Bloom Burton & Co. Limited acted as agent in connection with the Private Placement. ATE.VN: 0.170 (+0.010)
Antibe Therapeutics Announces Completion of Validation Studies of ATB-346, Progression to Phase 2 Clinical Trials
BusinessWire - Mon Dec 21, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe"
(TSXV: ATE, OTCQX: ATBPF) announced today the completion of the previously announced validation studies being performed on the Company's lead drug, ATB-346. These studies were initiated as a consequence of ATB-346 inducing an elevation of liver enzymes in some subjects taking the higher doses of the drug (750 and 1500 mg/day), and were aimed at gaining a better understanding of the drug's potency, absorption, metabolism and excretion characteristics. The results of these studies support progression to Phase 2 of development of this drug in patients with osteoarthritis. ATE.VN: 0.170 (+0.010)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 16.57 (-0.04), PFE: 36.83 (+0.05), AMGN: 167.67 (+1.11), AMPE: 0.95 (unch), LLY: 82.09 (+0.11), NKTR: 15.15 (-0.16), AGN: 248.95 (+1.10), AZN: 30.91 (-0.24), ABBV: 64.45 (+0.13), POZN: 5.94 (-0.43), REGN: 398.27 (+3.37), PTIE: 2.68 (-0.02)
Antibe Therapeutics Reports Q2 2016 Interim Financial and Operating Results and Appoints New CFO
BusinessWire - Tue Dec 01, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe"
(TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015. The Corporation's unaudited Q2 2016 financial statements and MD&A are available on SEDAR. ATE.VN: 0.170 (+0.010)
(0)
(0)